These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T; J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218 [TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. Small EJ; Carroll PR Urology; 1994 Mar; 43(3):408-10. PubMed ID: 7510915 [TBL] [Abstract][Full Text] [Related]
5. Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. Schellhammer PF; Venner P; Haas GP; Small EJ; Nieh PT; Seabaugh DR; Patterson AL; Klein E; Wajsman Z; Furr B; Chen Y; Kolvenbag GJ J Urol; 1997 May; 157(5):1731-5. PubMed ID: 9112515 [TBL] [Abstract][Full Text] [Related]
6. A controlled trial of Casodex (bicalutamide) vs. flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Casodex Combination Study Group. Soloway MS; Schellhammer P; Sharifi R; Venner P; Patterson AL; Sarosdy M; Vogelzang N; Jones J; Kolvenbag G Eur Urol; 1996; 29 Suppl 2():105-9. PubMed ID: 8717471 [TBL] [Abstract][Full Text] [Related]
7. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. Scher HI; Kelly WK J Clin Oncol; 1993 Aug; 11(8):1566-72. PubMed ID: 7687666 [TBL] [Abstract][Full Text] [Related]
10. [The antiandrogen withdrawal syndrome: decrease in prostate specific antigen serum levels after withdrawal of antiandrogens]. Hornák M; Bárdos A; Goncalves F Rozhl Chir; 1997 Sep; 76(9):435-7. PubMed ID: 9471771 [TBL] [Abstract][Full Text] [Related]
11. [Anti-androgen withdrawal syndrome]. Breul J; Paul R Urologe A; 1998 Mar; 37(2):156-8. PubMed ID: 9563126 [TBL] [Abstract][Full Text] [Related]
12. Clinical progress with a new antiandrogen, Casodex (bicalutamide). Blackledge GR Eur Urol; 1996; 29 Suppl 2():96-104. PubMed ID: 8717470 [TBL] [Abstract][Full Text] [Related]
13. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group. Schellhammer P; Sharifi R; Block N; Soloway M; Venner P; Patterson AL; Sarosdy M; Vogelzang N; Jones J; Kolvenbag G Urology; 1995 May; 45(5):745-52. PubMed ID: 7538237 [TBL] [Abstract][Full Text] [Related]
14. Bicalutamide (Casodex) in the treatment of prostate cancer: history of clinical development. Kolvenbag GJ; Blackledge GR; Gotting-Smith K Prostate; 1998 Jan; 34(1):61-72. PubMed ID: 9428389 [TBL] [Abstract][Full Text] [Related]
15. Casodex 10-200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer. An overview of the efficacy, tolerability and pharmacokinetics from three phase II dose-ranging studies. Casodex Study Group. Tyrrell CJ; Denis L; Newling D; Soloway M; Channer K; Cockshott ID Eur Urol; 1998; 33(1):39-53. PubMed ID: 9471040 [TBL] [Abstract][Full Text] [Related]
16. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. Scher HI; Liebertz C; Kelly WK; Mazumdar M; Brett C; Schwartz L; Kolvenbag G; Shapiro L; Schwartz M J Clin Oncol; 1997 Aug; 15(8):2928-38. PubMed ID: 9256137 [TBL] [Abstract][Full Text] [Related]
17. Prior administration of a non-steroidal anti-androgen failed to prevent the flare-up caused by a luteinizing hormone-releasing hormone agonist in a patient with metastatic prostate cancer. Uehara S; Yuasa T; Fujii Y; Yano A; Yamamoto S; Masuda H; Fukui I; Yonese J BMC Res Notes; 2015 Aug; 8():335. PubMed ID: 26242866 [TBL] [Abstract][Full Text] [Related]
18. The development of Casodex (bicalutamide): preclinical studies. Furr BJ Eur Urol; 1996; 29 Suppl 2():83-95. PubMed ID: 8717469 [TBL] [Abstract][Full Text] [Related]
19. Long-term effectiveness of luteinizing hormone-releasing hormone agonist or antiandrogen monotherapy in elderly men with localized prostate cancer (T1-2): a retrospective study. Raina R; Pahalajani G; Agarwal A; Zippe C Asian J Androl; 2007 Mar; 9(2):253-8. PubMed ID: 17334592 [TBL] [Abstract][Full Text] [Related]
20. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. Kelly WK; Scher HI J Urol; 1993 Mar; 149(3):607-9. PubMed ID: 7679759 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]